Literature DB >> 20157054

C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease.

Rongxin Zhang1, Yuan Yuan Zhang, Xiao R Huang, Yin Wu, Arthur C K Chung, Ed Xuekui Wu, Alexander J Szalai, Benjamin C Y Wong, Chu-Pak Lau, Hui Y Lan.   

Abstract

C-reactive protein (CRP) is a risk factor or biomarker for cardiovascular diseases, including hypertension. The present study investigated the functional importance of human CRP in hypertensive cardiac remodeling by a chronic infusion of angiotensin II (Ang II) into mice that express human CRP. Compared with the wild-type mice, although Ang II infusion caused an equally high systolic blood pressure, levels of human CRP were further elevated, and cardiac remodeling was markedly exacerbated in mice that express human CRP, resulting in a significant reduction in the left ventricular ejection fraction and fractional shortening and an increase in cardiac fibrosis (collagen I and III and alpha-smooth muscle actin) and inflammation (interleukin 1beta and tumor necrosis factor-alpha). The enhancement in cardiac remodeling in mice that express human CRP was associated with further upregulation of the Ang II type I receptor and transforming growth factor-beta1 and overactivation of both transforming growth factor-beta/Smad and nuclear factor-kappaB signaling pathways. Furthermore, in vitro studies in cardiac fibroblasts revealed that CRP alone was able to significantly induce expression of the Ang II type I receptor, collagen I/III, and alpha-smooth muscle actin, as well as proinflammation cytokines (interleukin 1beta and tumor necrosis factor-alpha), which was further enhanced by addition of Ang II. In conclusion, CRP is not only a biomarker but also a mediator in Ang II-mediated cardiac remodeling. Enhanced upregulation of the Ang II type I receptor and activation of the transforming growth factor-beta/Smad and nuclear factor-kappaB signaling pathways may be the mechanisms by which CRP promotes cardiac fibrosis and inflammation under high Ang II conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20157054     DOI: 10.1161/HYPERTENSIONAHA.109.140608

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  43 in total

1.  Fibrosis-related biomarkers and large and small vessel disease: the Cardiovascular Health Study.

Authors:  Isha Agarwal; Alice Arnold; Nicole L Glazer; Eddy Barasch; Luc Djousse; Annette L Fitzpatrick; John S Gottdiener; Joachim H Ix; Richard A Jensen; Jorge R Kizer; Eric B Rimm; David S Siscovick; Russell P Tracy; Tien Y Wong; Kenneth J Mukamal
Journal:  Atherosclerosis       Date:  2015-02-16       Impact factor: 5.162

2.  Eicosapentaenoic acid suppresses adverse effects of C-reactive protein overexpression on pressure overload-induced cardiac remodeling.

Authors:  Toshiyuki Nagai; Toshihisa Anzai; Yoshinori Mano; Hidehiro Kaneko; Atsushi Anzai; Yasuo Sugano; Yuichiro Maekawa; Toshiyuki Takahashi; Tsutomu Yoshikawa; Keiichi Fukuda
Journal:  Heart Vessels       Date:  2012-08-09       Impact factor: 2.037

3.  Plasma levels of matrix metalloproteinase-8 in patients with carotid atherosclerosis.

Authors:  Tamara Djurić; Maja Zivković; Aleksandra Stanković; Ana Kolaković; Djole Jekić; Vesna Selaković; Dragan Alavantić
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

4.  C-reactive protein promotes acute kidney injury via Smad3-dependent inhibition of CDK2/cyclin E.

Authors:  Weiyan Lai; Ying Tang; Xiao R Huang; Patrick Ming-Kuen Tang; Anping Xu; Alexander J Szalai; Tan-Qi Lou; Hui Y Lan
Journal:  Kidney Int       Date:  2016-07-26       Impact factor: 10.612

5.  C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes.

Authors:  F Liu; H Y Chen; X R Huang; A C K Chung; L Zhou; P Fu; A J Szalai; H Y Lan
Journal:  Diabetologia       Date:  2011-07-09       Impact factor: 10.122

Review 6.  Cardiac Fibrosis: The Fibroblast Awakens.

Authors:  Joshua G Travers; Fadia A Kamal; Jeffrey Robbins; Katherine E Yutzey; Burns C Blaxall
Journal:  Circ Res       Date:  2016-03-18       Impact factor: 17.367

7.  Angiotensin II-induced dilated cardiomyopathy in Balb/c but not C57BL/6J mice.

Authors:  Hongmei Peng; Xiao-Ping Yang; Oscar A Carretero; Pablo Nakagawa; Martin D'Ambrosio; Pablo Leung; Jiang Xu; Edward L Peterson; Germán E González; Pamela Harding; Nour-Eddine Rhaleb
Journal:  Exp Physiol       Date:  2011-05-20       Impact factor: 2.969

8.  Fragmented QRS complex predicts contrast-induced nephropathy and in-hospital mortality after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.

Authors:  Alparslan Kurtul; Mustafa Duran
Journal:  Clin Cardiol       Date:  2017-02-28       Impact factor: 2.882

9.  Fibrosis-related biomarkers and risk of total and cause-specific mortality: the cardiovascular health study.

Authors:  Isha Agarwal; Nicole L Glazer; Eddy Barasch; Mary L Biggs; Luc Djoussé; Annette L Fitzpatrick; John S Gottdiener; Joachim H Ix; Jorge R Kizer; Eric B Rimm; David S Siscovick; Russell P Tracy; Susan J Zieman; Kenneth J Mukamal
Journal:  Am J Epidemiol       Date:  2014-04-25       Impact factor: 4.897

10.  Fibrosis-related biomarkers and incident cardiovascular disease in older adults: the cardiovascular health study.

Authors:  Isha Agarwal; Nicole L Glazer; Eddy Barasch; Mary L Biggs; Luc Djousse; Annette L Fitzpatrick; John S Gottdiener; Joachim H Ix; Jorge R Kizer; Eric B Rimm; David S Sicovick; Russell P Tracy; Kenneth J Mukamal
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.